false 0001533743 0001533743 2024-02-20 2024-02-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 20, 2024

 

Commission file number 001-39531

 

PROCESSA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in its Charter)

 

Delaware   45-1539785
(State or Other Jurisdiction of
Incorporation or Organization)		   (I.R.S. Employer
Identification Number)

 

7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076

 

(Address of Principal Executive Offices, Including Zip Code)

 

(443) 776-3133

 

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common stock: Par value $.0001   PCSA   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01. Regulation Disclosure.

 

Mr. George Ng, CEO for Processa Pharmaceuticals, Inc. (“Processa”) presented at the Winter Wrap-Up MicroCap Rodeo Conference on February 20, 2024.

 

Processa’s presentation is furnished as Exhibit 99.1 and will also be made available in the “Investors” section on Processa’s website, located at https://www.processapharmaceuticals.com.

 

Processa undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through other public disclosure, including in the “Investors” section of Processa’s website. Processa routinely uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Description
99.1   Processa Pharmaceuticals Presentation dated February 20, 2024
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on February 21, 2024.

 

  PROCESSA PHARMACEUTICALS, INC.
  Registrant
     
  By: /s/ George Ng
    George Ng
    Chief Executive Officer

 

 

 

Exhibits 99.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

v3.24.0.1
Cover
Feb. 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 20, 2024
Entity File Number 001-39531
Entity Registrant Name PROCESSA PHARMACEUTICALS, INC.
Entity Central Index Key 0001533743
Entity Tax Identification Number 45-1539785
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7380 Coca Cola Drive
Entity Address, Address Line Two Suite 106
Entity Address, City or Town Hanover
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21076
City Area Code (443)
Local Phone Number 776-3133
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock: Par value $.0001
Trading Symbol PCSA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Processa Pharmaceuticals Charts.
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Processa Pharmaceuticals Charts.